• Save

23/06/2020

European clinicians share their local perspectives on practice changing studies from EHA25 Virtual

MEDtalks in association with The European Hematology Association has launched a series of four webinars, covering some of the most important practice changing studies presented at EHA25 Virtual. We invited leading European clinicians and study authors from the UK, Germany, Spain, the Netherlands and Switzerland to discuss the relevance of these studies for their local clinical practice. The webinar series was divided into the following topics: Multiple Myeloma & CAR-T, Lymphoma, CLL and AML. You can watch the webinars below: Multiple myeloma & CAR-T Webinar Lymphomas Webinar CLL Webinar AML Webinar All webinars are moderated by PD Dr. med. Jens Ulrich Rüffer. The webinars are independently produced and paid for by the MEDtalks Group of Companies.

00:41:04

• Save

Congress news 23/06/2020

EHA 25 European Perspectives Webinar on Multiple Myeloma & CAR-T

In this webinar, Prof. Dr. John Gribben, Prof. Dr. Valentín Ortiz and PD Prof. Dr. Dr. Udo Holtick discuss three practice changing studies on Multiple Myeloma/CAR-T. Study 1 summarised by Prof. Dr. John Gribben IXAZOMIB VS PLACEBO AS POST-INDUCTION MAINTENANCE THERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS (PTS) NOT UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANT (ASCT): PHASE 3 TOURMALINE-MM4 TRIAL Study 2 summarised by Prof. Dr. Valentín Ortiz IDECABTAGENE VICLEUCEL (IDE-CEL; BB2121), A BCMA-TARGETED CAR T CELL THERAPY, IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: INITIAL KARMMA RESULTS Study 3 summarised by PD Prof. Dr. Dr. Udo Holtick LB2603 ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY   The webinar was independently produced and paid for by the MEDtalks Group of Companies.

00:44:19

• Save

Congress news 23/06/2020

EHA 25 European Perspectives Webinar on Lymphomas

In this webinar, Prof. Dr. Peter Borchmann and Dr. Robert Marcus discuss three practice changing studies on Lymphomas. Study 1 summarised by Prof. Dr. Peter Borchmann (S101) POSITRON EMISSION TOMOGRAPHY GUIDED OMISSION OF RADIOTHERAPY IN EARLY-STAGE UNFAVORABLE HODGKIN LYMPHOMA: FINAL RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE III HD17 TRIAL BY THE GHSG and INTERIM ANALYSIS OF ZUMA-5: A PHASE 2 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA (CARON A. JACOBSON) Study 2 summarised by Dr. Robert Marcus ROLE OF RADIOTHERAPY AND DOSE-DENSIFICATION OF R-CHOP IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA: A SUBGROUP ANALYSIS OF THE UNFOLDER TRIAL OF THE GERMAN LYMPHOMA ALLIANCE (GLA)   The webinar was independently produced and paid for by the MEDtalks Group of Companies.

00:41:50

• Save

Congress news 23/06/2020

EHA 25 European Perspectives Webinar on CLL

In this webinar, Prof. Dr. Arnon Kater, Prof. Dr. Clemens Wendtner and Prof. Dr. Davide Rossi discuss three practice changing studies on CLL. Study 1 summarised by Prof. Dr. Arnon Kater EFFICACY OF VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: PRIMARY ENDPOINT ANALYSIS OF THE INTERNATIONAL PHASE 3B TRIAL (VENICE I) Study 2 summarised by Prof. Dr. Clemens Wendtner S155: FIXED-DURATION VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: FOLLOW-UP OF EFFICACY AND SAFETY RESULTS FROM THE MULTICENTER, OPEN-LABEL, RANDOMIZED PHASE 3 CLL14 TRIAL Study 3 summarised by Prof. Dr. Davide Rossi S 158: FIRST-LINE IBRUTINIB (IBR) + VENETOCLAX (VEN) FOR PATIENTS (PTS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): EFFICACY AND SAFETY RESULTS FROM CAPTIVATE MRD COHORT   The webinar was independently produced and paid for by the MEDtalks Group of Companies.

00:30:30

• Save

Congress news 23/06/2020

EHA 25 European Perspectives Webinar on AML

In this webinar, Prof. Dr. Nigel Russel, MD and Prof. Dr. Gert Ossenkoppele discuss two practice changing studies on AML. Study 1 summarised by Prof. Dr. Nigel Russell MD (S144) THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IS WELL-TOLERATED AND EFFECTIVE IN AML PATIENTS: PHASE 1B RESULTS Study 2 summarised by Prof. Dr. Gert Ossenkoppele (LB2601) A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VENETOCLAX WITH AZACITIDINE VS AZACITIDINE IN TREATMENT-NAÏVE PATIENTS WITH ACUTE MYELOID LEUKEMIA INELIGIBLE FOR INTENSIVE THERAPY-VIALE-A   The webinar was independently produced and paid for by the MEDtalks Group of Companies.